The Alzheimer's Drug Discovery Foundation supports promising, diverse international research projects to develop new drugs for Alzheimer's and related dementias, including vascular, Lewy body, and frontotemporal dementias.

Our goal is to fill the critical translational funding gap. We fund four categories of research:

  1. Drug discovery
  2. Clinical trials
  3. Biomarkers
  4. Prevention

The ADDF is interested in novel targets and therapeutic approaches for Alzheimer's disease and related dementia, and we are open to small molecule, biologic, and gene therapy approaches. Because the underlying mechanisms of Alzheimer's are complex, we maintain a diverse portfolio of drug targets. We invite you to explore our portfolio to learn more about funded projects. Our current RFPs and deadlines are available on the Funding Opportunities page.

Our Current Portfolio by Drug Targets and Examples of Each


• Calcium regulation
• Growth/neurotrophic factors
• Neuronal degeneration
• Neuronal regeneration and repair
• Oxidative stress

Misfolded Proteins

• Proteostasis
• Tau, TDP43, Synuclein


• Neuroinflammation
• Systemic inflammation

Genetics & Epigenetics

• Epigenetics


• Cognitive and functional outcomes
• CSF and blood-based biomarkers
• Neuroimaging and functional activity measure

Mitochondria & Metabolic Function

Synaptic Activity & Neurotransmitters



• Endocrinology
• Models and resource development
• Pharmacoeconomics


Please note: The ADDF no longer funds anti-amyloid approaches and has limited interest in funding cholinesterase inhibitor programs.